CRISPR THERAPEUTICS AG Revenue from Related Parties
CRISPR THERAPEUTICS AG (CRSP) reported Revenue from Related Parties of $318.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-27.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2022-02-15
- CRISPR THERAPEUTICS AG revenue from related parties for the quarter ending 2019-12-31 was $69.00K, a 90.39% decline year-over-year.
- CRISPR THERAPEUTICS AG revenue from related parties for the quarter ending 2019-09-30 was $31.00K, a 93.00% decline year-over-year.
- CRISPR THERAPEUTICS AG revenue from related parties for the quarter ending 2019-06-30 was $318.00K, a 63.90% decline year-over-year.
- CRISPR THERAPEUTICS AG revenue from related parties for the quarter ending 2019-03-31 was $328.00K, a 69.69% decline year-over-year.
- CRISPR THERAPEUTICS AG revenue from related parties for fiscal 2019 was $746.00K, a 76.12% decline from fiscal 2018.
- CRISPR THERAPEUTICS AG revenue from related parties for fiscal 2018 was $3.12M, a 34.37% decline from fiscal 2017.
- CRISPR THERAPEUTICS AG revenue from related parties for fiscal 2017 was $4.76M, a 300.00% increase from fiscal 2016.
- CRISPR THERAPEUTICS AG revenue from related parties for fiscal 2016 was $1.19M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 3 month as first filed | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 9 month as first filed | Revenue from Related Parties 12 month |
|---|---|---|---|---|---|---|
| 2020-06-30 | $318.00K 10-Q · filed 2020-07-27 | |||||
| 2019-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $100.00K derived: sum of 2 quarters · filed 2022-02-15 | $418.00K derived: sum of 3 quarters · filed 2022-02-15 | $746.00K 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $31.00K 10-Q · filed 2020-10-28 | $211.93M 10-Q · filed 2019-10-28 | $349.00K derived: sum of 2 quarters · filed 2020-10-28 | $677.00K 10-Q · filed 2020-10-28 | $212.57M 10-Q · filed 2019-10-28 | $1.40M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $318.00K 10-Q · filed 2019-07-29 | $646.00K 10-Q · filed 2020-07-27 | $1.36M derived: sum of 3 quarters · filed 2021-02-16 | $1.81M derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2019-03-31 | $328.00K 10-Q · filed 2020-04-28 | $1.05M derived: sum of 2 quarters · filed 2021-02-16 | $1.49M derived: sum of 3 quarters · filed 2021-02-16 | $2.37M derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2018-12-31 | $718.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $1.16M derived: sum of 2 quarters · filed 2021-02-16 | $2.04M derived: sum of 3 quarters · filed 2021-02-16 | $3.12M 10-K · filed 2021-02-16 | ||
| 2018-09-30 | $443.00K 10-Q · filed 2019-10-28 | $1.32M derived: sum of 2 quarters · filed 2019-10-28 | $2.41M 10-Q · filed 2019-10-28 | $3.28M derived: sum of 4 quarters · filed 2020-02-12 | ||
| 2018-06-30 | $881.00K 10-Q · filed 2019-07-29 | $1.96M 10-Q · filed 2019-07-29 | $2.83M derived: sum of 3 quarters · filed 2020-02-12 | $4.08M derived: sum of 4 quarters · filed 2020-02-12 | ||
| 2018-03-31 | $1.08M 10-Q · filed 2019-04-29 | $1.95M derived: sum of 2 quarters · filed 2020-02-12 | $3.20M derived: sum of 3 quarters · filed 2020-02-12 | $4.68M derived: sum of 4 quarters · filed 2020-02-12 | ||
| 2017-12-31 | $872.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $2.12M derived: sum of 2 quarters · filed 2020-02-12 | $3.60M derived: sum of 3 quarters · filed 2020-02-12 | $4.76M 10-K · filed 2020-02-12 | ||
| 2017-09-30 | $1.25M 10-Q · filed 2018-11-07 | $2.72M derived: sum of 2 quarters · filed 2018-11-07 | $3.89M 10-Q · filed 2018-11-07 | $4.69M derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-06-30 | $1.48M 10-Q · filed 2018-08-07 | $2.64M 10-Q · filed 2018-08-07 | $3.44M derived: sum of 3 quarters · filed 2019-02-25 | $3.83M derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-03-31 | $1.16M 10-Q · filed 2018-05-08 | $1.97M derived: sum of 2 quarters · filed 2019-02-25 | $2.35M derived: sum of 3 quarters · filed 2019-02-25 | |||
| 2016-12-31 | $805.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.19M derived: sum of 2 quarters · filed 2019-02-25 | $1.19M 10-K · filed 2019-02-25 | |||
| 2016-09-30 | $385.00K 10-Q · filed 2017-11-08 | $385.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |